(Q56970710)

Anna Dominiczak

10

0 references

Luis Miguel Ruilope

Luis Ruilope

27

0 references

Alberto Zanchetti

Alberto Zanchetti

32

0 references

Krzysztof Narkiewicz

Krzysztof Narkiewicz

21

0 references

Giuseppe Mancia

1

Giuseppe Mancia

0 references

Sverre E. Kjeldsen

17

Sverre E. Kjeldsen

0 references

Hermann Haller

15

Hermann Haller

0 references

Roland E. Schmieder

28

Roland E. Schmieder

0 references

Guido Grassi

14

Guido Grassi

0 references

author name string

Stéphane Laurent

2

0 references

Enrico Agabiti-Rosei

3

0 references

Ettore Ambrosioni

4

0 references

Michel Burnier

5

0 references

Mark J. Caulfield

6

0 references

Denis Clément

8

0 references

Antonio Coca

9

0 references

Serap Erdine

11

0 references

Robert Fagard

12

0 references

Csaba Farsang

13

0 references

Antony Heagerty

16

0 references

Wolfgang Kiowski

18

0 references

Jean Michel Mallion

19

0 references

Athanasios Manolis

20

0 references

Peter Nilsson

22

0 references

Michael H. Olsen

23

0 references

Karl Heinz Rahn

24

0 references

Josep Redon

25

0 references

José Rodicio

26

0 references

Harry A.J. Struijker-Boudier

29

0 references

Pieter A. Van Zwieten

30

0 references

Margus Viigimaa

2007 Guidelines for the Management of Arterial Hypertension

31

0 references

publication date

January 2009

0 references

number of pages

40

1 reference

based on heuristic

inferred from page(s)

published in

Blood Pressure

0 references

volume

18

0 references

issue

6

0 references

page(s)

308-347

0 references

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Left ventricular hypertrophy and cardiovascular mortality by race and ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Left ventricular architecture and survival in African-Americans free of coronary heart disease (from the Atherosclerosis Risk in Communities [ARIC] study)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Clinical significance of left ventricular hypertrophy and changes in left ventricular mass in high-risk hypertensive patients: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Which markers of subclinical organ damage to measure in individuals with high normal blood pressure?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Cardio-renal organ damage and cardiovascular outcomes in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Definition of Kidney Dysfunction as a Cardiovascular Risk Factor Use of Urinary Albumin Excretion and Estimated Glomerular Filtration Rate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Target organ damage: how to detect it and how to treat it?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Albuminuria: a target for treatment of type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Detection of silent cerebrovascular disease refines risk stratification of hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Increased wall:lumen ratio of retinal arterioles in male patients with a history of a cerebrovascular event

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Prognostic role of flow-mediated dilatation of the brachial artery in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Multiple biomarkers for the prediction of first major cardiovascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Relation of Left Ventricular Mass and Geometry to Morbidity and Mortality in Uncomplicated Essential Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Expert consensus document on arterial stiffness: methodological issues and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Management of hypertension in peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Prognostic significance of left ventricular mass change during treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Is prehypertension an independent predictor of target organ changes in young-to-middle-aged persons of African descent?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Stroke and coronary heart disease in treated hypertension -- a prospective cohort study over three decades

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Pr

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Latin American guidelines on hypertension. Latin American Expert Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by rep

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Treatment of hypertension in patients 80 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Telmisartan to prevent recurrent stroke and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Lowering blood pressure reduces renal events in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Feasibility of treating prehypertension with an angiotensin-receptor blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Large and small artery cross-talk and recent morbidity-mortality trials in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

The Risk of Myocardial Infarction Associated With Antihypertensive Drug Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Long-term follow-up after tight control of blood pressure in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Aortic diameter, wall stiffness, and wave reflection in systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

New-onset diabetes and antihypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Diabetes and cardiovascular events in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

A comparison of atenolol and nebivolol in isolated systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Nebivolol induces parallel improvement of left ventricular filling pressure and coronary flow reserve in uncomplicated arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind t

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Angiotensin receptor blockers and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Benefits and safety of long-acting calcium antagonists in coronary artery disease: the Action Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Therapeutic potential of renin inhibitors in the management of cardiovascular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Renin inhibition with aliskiren: where are we now, and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

N-terminal pro-brain natriuretic peptide A new gold standard in predicting mortality in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Resistant hypertension: an overview of evaluation and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Global burden of hypertension: analysis of worldwide data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Management of antihypertensive drugs in three European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Olmesartan medoxomil/amlodipine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Single-pill combination of amlodipine and valsartan in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Fixed-dose combinations improve medication compliance: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Results of the pilot study for the Hypertension in the Very Elderly Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of age on the cardiac and vascular limbs of the arterial baroreflex.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effect of telmisartan on renal outcomes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Irbesartan in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Losartan and prevention of atrial fibrillation recurrence in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Valsartan for prevention of recurrent atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effect of treating erectile dysfunction on management of systolic hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Two decades of progress in preventing vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

A strategy to reduce cardiovascular disease by more than 80%

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Left Ventricular Geometry and Survival in Patients With Normal Left Ventricular Ejection Fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468

Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037050903450468